The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2022 Feb 8

PMID 35131885

Authors

Veronique Ouellet

Andrew Erickson

Kathy Wiley

Colm Morrissey

Viktor Berge

Carlos S Moreno

Kristin Austlid Tasken

Dominique Trudel

Lawrence D True

Michael S Lewis

Aud Svindland

Onur Ertunc

Igor Damasceno Vidal

Adeboye O Osunkoya

Tracy Jones

G Steven Bova

Tarja Lamminen

Ariel H Achtman

Mark Buzza

Michelle M Kouspou

Steven A Bigler

Xinchun Zhou

Stephen J Freedland

Anne-Marie Mes-Masson

Isla P Garraway

Bruce J Trock

Pekka Taimen

Fred Saad

Tuomas Mirtti

Beatrice S Knudsen

Angelo M De Marzo

Affiliations

Soon will be listed here.

Abstract

Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations.

Methods: Three separate TMA sets were built that differ by purpose and disease state.

Results: The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases.

Conclusions: The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation.

Impact: This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.

Citing Articles

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy.

Bialas P, Kobayashi T, Hellsten R, Krzyzanowska A, Persson M, Marginean F Prostate. 2024; 85(3):252-264.

PMID: 39523927 PMC: 11720397. DOI: 10.1002/pros.24820.

References

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson P, True L . Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011; 6(11):e27970. PMC: 3219707. DOI: 10.1371/journal.pone.0027970. View

Silberstein J, Pal S, Lewis B, Sartor O . Current clinical challenges in prostate cancer. Transl Androl Urol. 2016; 2(3):122-36. PMC: 4708189. DOI: 10.3978/j.issn.2223-4683.2013.09.03. View

Darshan M, Zheng Q, Fedor H, Wyhs N, Yegnasubramanian S, Lee P . Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate. 2013; 74(1):61-9. PMC: 4020427. DOI: 10.1002/pros.22730. View

Schroder F, Hugosson J, Roobol M, Tammela T, Zappa M, Nelen V . Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384(9959):2027-35. PMC: 4427906. DOI: 10.1016/S0140-6736(14)60525-0. View

Loeb S, Bjurlin M, Nicholson J, Tammela T, Penson D, Carter H . Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014; 65(6):1046-55. PMC: 4113338. DOI: 10.1016/j.eururo.2013.12.062. View

Lotan T, Wei W, Morais C, Hawley S, Fazli L, Hurtado-Coll A . PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus. 2016; 2(2):180-188. PMC: 5014432. DOI: 10.1016/j.euf.2015.07.005. View

Roudier M, True L, Higano C, Vesselle H, Ellis W, Lange P . Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003; 34(7):646-53. DOI: 10.1016/s0046-8177(03)00190-4. View

Shah R, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M . Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004; 64(24):9209-16. DOI: 10.1158/0008-5472.CAN-04-2442. View

Lotan T, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J . PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011; 17(20):6563-73. PMC: 3195839. DOI: 10.1158/1078-0432.CCR-11-1244. View

10.

Baena-Del Valle J, Zheng Q, Hicks J, Fedor H, Trock B, Morrissey C . Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. Am J Clin Pathol. 2017; 148(5):398-415. PMC: 5848261. DOI: 10.1093/ajcp/aqx094. View

11.

Zhang X, Coleman I, Brown L, True L, Kollath L, Lucas J . SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015; 21(20):4698-708. PMC: 4609255. DOI: 10.1158/1078-0432.CCR-15-0157. View

12.

Guedes L, Morais C, Fedor H, Hicks J, Gurel B, Melamed J . Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Arch Pathol Lab Med. 2018; 143(3):338-348. DOI: 10.5858/arpa.2018-0068-OA. View

13.

Lotan T, Tomlins S, Bismar T, van der Kwast T, Grignon D, Egevad L . Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol. 2020; 44(7):e15-e29. DOI: 10.1097/PAS.0000000000001450. View

14.

Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J . Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4):222-234. PMC: 7472658. DOI: 10.1038/nrurol.2018.9. View

15.

Labrecque M, Coleman I, Brown L, True L, Kollath L, Lakely B . Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019; 129(10):4492-4505. PMC: 6763249. DOI: 10.1172/JCI128212. View

16.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

17.

Akfirat C, Zhang X, Ventura A, Berel D, Colangelo M, Miranti C . Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol. 2013; 230(3):291-7. PMC: 3926514. DOI: 10.1002/path.4180. View

18.

Haider M, Zhang X, Coleman I, Ericson N, True L, Lam H . Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. Clin Exp Metastasis. 2015; 33(3):239-48. PMC: 4777655. DOI: 10.1007/s10585-015-9773-7. View

19.

Faith D, Isaacs W, Morgan J, Fedor H, Hicks J, Mangold L . Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate. 2004; 61(3):215-27. PMC: 3715040. DOI: 10.1002/pros.20095. View

20.

Halushka M, Cornish T, Lu J, Selvin S, Selvin E . Creation, validation, and quantitative analysis of protein expression in vascular tissue microarrays. Cardiovasc Pathol. 2009; 19(3):136-46. PMC: 2866781. DOI: 10.1016/j.carpath.2008.12.007. View